• Sajjad Moradi, Nafiseh Shokri-Mashhadi, Sahar Saraf-Bank, Hamed Mohammadi, Mehdi Zobeiri, Cain C T Clark, and Mohammad Hossein Rouhani.
• Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
• Int. J. Clin. Pract. 2021 Nov 1; 75 (11): e14726.

ObjectiveA systematic review and meta-analysis was conducted to summarise studies conducted on the effects of artichoke supplementation on liver enzymes.MethodsSuitable studies were detected by searching online databases, including Medline, Embase, Cochrane Library, and Scopus databases, until 05 June 2021. As liver enzymes were reported in different units, standardised mean differences (SMD) were used and data were pooled using a random-effects model. Heterogeneity, publication bias, and sensitivity analysis were also assessed.ResultsPooled analysis, of eight clinical trials, revealed that artichoke supplementation significantly reduced the concentration of aspartate aminotransferase (AST) (P = .001) and alanine transaminase (ALT) (P = .016), in comparison with placebo. Subgroup analysis suggested that artichoke administration significantly reduces AST and ALT in patients with non-alcoholic fatty liver disease (P = .003 for AST and P < .001 for ALT), and ALT among overweight/obese subjects (P = .025).ConclusionsArtichoke supplementation elicited significant reductions in liver enzymes, especially among patients with non-alcoholic fatty liver disease.© 2021 John Wiley & Sons Ltd.

8 keywords...

hide…